SERUM GLIAL FIBRILLARY ACIDIC PROTEIN AS BIOMARKER IN NEONATES WITH HYPOXIC ISCHEMIC ENCEPHALOPATHY

Abstract

Introduction: Hypoxic ischemic encephalopathy (HIE) is a potentially devastating condition accounts for 25% of all neonatal deaths , 40% will be affected by blindness, deafness, autism,, epilepsy, or other long-term complications( Felipe et al., 2013). Aim of work: Assessment of the level of serum glial fibrillary acidic protein (GFAP) in neonate with hypoxic ischemic encephalopathy to early identify neonates with poor prognosis. Patients and Methods: This study is a case-control study was carried out on 50 neonates babies, they were selected from (NICU) of Bab Elsharia hospital in Cairo during the period from October 2016 to March 2018. Results: In our study we found that there was statistically significant correlation between GFAP at 24 hours age and this demonstrate a concentration-dependent relationship between serum GFAP at birth and the severity of encephalopathy (Chalak et al. (2014). Conclusion: Serial increase in level GFAP from birth in HIE neonates and the severity of the hypoxic-ischemic injury can be stratified at birth and postnatal because elevated GFAP in serum correlated with severity of HIE. Recommendations: Measurement of serum GFAP in HIE within 24 hours postnatal but with large sample to early identify neonates with poor prognosis.